Literature DB >> 23530980

Rate and predictors of non-AIDS events in a cohort of HIV-infected patients with a CD4 T cell count above 500 cells/mm³.

Constanza Lucero1, Berta Torres, Agathe León, Marta Calvo, Lorna Leal, Iñaki Pérez, Montserrat Plana, Mireia Arnedo, Josep Mallolas, Josep M Gatell, Felipe García.   

Abstract

The reduction of risk of non-AIDS events after combined antiretroviral therapy (cART) initiation and the crude incidence rate (CIR) of these events in patients who control the viral load without cART (controllers) in a cohort of 574 antiretroviral-naive patients with a baseline CD4 T cell count above 500 cells/mm³ were assessed. Non-AIDS severe events were defined as a first admission to the hospital due to non-AIDS-defining malignancies, cardiovascular, neuropsychiatric, liver-related, or end-stage renal disease events. Potential determinants of non-AIDS/death events were studied using Cox regression models. Eighty-five non-AIDS/death events occurred during 6,062 persons-years of follow-up (PYFU) with a CIR of 1.4 per 100 PYFU. Factors associated with non-AIDS/death event were age (HR 3.4; 95% CI: 1.6-6.9), nadir CD4 below 350 cells/mm³ (HR 2.5; 95% CI: 1.4-4.6), and a last determination of viral load above the median (HR 1.9; 95% CI: 1.0-3.3). The CIR of non-AIDS/death events was 2.1 and 1.8 per 100 PYFU before and after cART in patients who started cART (n=446). A reduction of CIR of non-AIDS events after cART initiation was observed only in patients with a nadir of CD4 above 350 cells/mm³ (2.5 vs. 0.6 per 100 PYFU, p=0.004, and remained stable after cART in patients with a median nadir of CD4 below 350 cells/mm³. CIR was similar in elite, viremic, and noncontrollers (1.1, 1.0, and 1.5 per 100 PYFU, respectively, p=0.25). Reduction of CIR of non-AIDS events after cART initiation depends on nadir CD4 T cell count. Most of the controllers patients had a CIR similar to noncontrollers. These data support the early initiation of cART in HIV-infected patients.

Entities:  

Mesh:

Year:  2013        PMID: 23530980      PMCID: PMC3715811          DOI: 10.1089/AID.2012.0367

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  31 in total

Review 1.  Care of patients with hepatitis C and HIV co-infection.

Authors:  Vincent Soriano; Massimo Puoti; Mark Sulkowski; Stefan Mauss; Patrice Cacoub; Antonietta Cargnel; Douglas Dieterich; Angelos Hatzakis; Jurgen Rockstroh
Journal:  AIDS       Date:  2004-01-02       Impact factor: 4.177

2.  The association of CD4+ T-cell counts and cardiovascular risk in treated HIV disease.

Authors:  Jennifer E Ho; Rebecca Scherzer; Frederick M Hecht; Kristinalisa Maka; Van Selby; Jeffrey N Martin; Peter Ganz; Steven G Deeks; Priscilla Y Hsue
Journal:  AIDS       Date:  2012-06-01       Impact factor: 4.177

3.  Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.

Authors:  J W Mellors; A Muñoz; J V Giorgi; J B Margolick; C J Tassoni; P Gupta; L A Kingsley; J A Todd; A J Saah; R Detels; J P Phair; C R Rinaldo
Journal:  Ann Intern Med       Date:  1997-06-15       Impact factor: 25.391

4.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

5.  The prevalence and incidence of neurocognitive impairment in the HAART era.

Authors:  Kevin R Robertson; Marlene Smurzynski; Thomas D Parsons; Kunling Wu; Ronald J Bosch; Julia Wu; Justin C McArthur; Ann C Collier; Scott R Evans; Ron J Ellis
Journal:  AIDS       Date:  2007-09-12       Impact factor: 4.177

6.  Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata.

Authors:  Frank J Palella; Maria Deloria-Knoll; Joan S Chmiel; Anne C Moorman; Kathleen C Wood; Alan E Greenberg; Scott D Holmberg
Journal:  Ann Intern Med       Date:  2003-04-15       Impact factor: 25.391

7.  Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.

Authors:  Peter W Hunt; Jason Brenchley; Elizabeth Sinclair; Joseph M McCune; Michelle Roland; Kimberly Page-Shafer; Priscilla Hsue; Brinda Emu; Melissa Krone; Harry Lampiris; Daniel Douek; Jeffrey N Martin; Steven G Deeks
Journal:  J Infect Dis       Date:  2008-01-01       Impact factor: 5.226

8.  Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease.

Authors:  Robert C Kalayjian; Nora Franceschini; Samir K Gupta; Lynda A Szczech; Ezekiel Mupere; Ronald J Bosch; Marlene Smurzynski; Jeffrey M Albert
Journal:  AIDS       Date:  2008-02-19       Impact factor: 4.177

9.  CD4+ count-guided interruption of antiretroviral treatment.

Authors:  W M El-Sadr; J D Lundgren; J D Neaton; F Gordin; D Abrams; R C Arduino; A Babiker; W Burman; N Clumeck; C J Cohen; D Cohn; D Cooper; J Darbyshire; S Emery; G Fätkenheuer; B Gazzard; B Grund; J Hoy; K Klingman; M Losso; N Markowitz; J Neuhaus; A Phillips; C Rappoport
Journal:  N Engl J Med       Date:  2006-11-30       Impact factor: 91.245

10.  Microbial translocation is a cause of systemic immune activation in chronic HIV infection.

Authors:  Jason M Brenchley; David A Price; Timothy W Schacker; Tedi E Asher; Guido Silvestri; Srinivas Rao; Zachary Kazzaz; Ethan Bornstein; Olivier Lambotte; Daniel Altmann; Bruce R Blazar; Benigno Rodriguez; Leia Teixeira-Johnson; Alan Landay; Jeffrey N Martin; Frederick M Hecht; Louis J Picker; Michael M Lederman; Steven G Deeks; Daniel C Douek
Journal:  Nat Med       Date:  2006-11-19       Impact factor: 53.440

View more
  22 in total

1.  Delayed-type hypersensitivity and hepatitis B vaccine responses, in vivo markers of cellular and humoral immune function, and the risk of AIDS or death.

Authors:  Shane B Patterson; Michael L Landrum; Jason F Okulicz
Journal:  Vaccine       Date:  2014-04-29       Impact factor: 3.641

Review 2.  Cardiovascular disease and HIV infection.

Authors:  Virginia A Triant
Journal:  Curr HIV/AIDS Rep       Date:  2013-09       Impact factor: 5.071

Review 3.  Impact of antiretroviral therapy (ART) timing on chronic immune activation/inflammation and end-organ damage.

Authors:  Reena Rajasuriar; Edwina Wright; Sharon R Lewin
Journal:  Curr Opin HIV AIDS       Date:  2015-01       Impact factor: 4.283

4.  Hospitalization Rates and Reasons Among HIV Elite Controllers and Persons With Medically Controlled HIV Infection.

Authors:  Trevor A Crowell; Kelly A Gebo; Joel N Blankson; P Todd Korthuis; Baligh R Yehia; Richard M Rutstein; Richard D Moore; Victoria Sharp; Ank E Nijhawan; W Christopher Mathews; Lawrence H Hanau; Roberto B Corales; Robert Beil; Charurut Somboonwit; Howard Edelstein; Sara L Allen; Stephen A Berry
Journal:  J Infect Dis       Date:  2014-12-15       Impact factor: 5.226

5.  History of AIDS in HIV-Infected Patients Is Associated With Higher In-Hospital Mortality Following Admission for Acute Myocardial Infarction and Stroke.

Authors:  Nwora Lance Okeke; Charles B Hicks; Mehri S McKellar; Vance G Fowler; Jerome J Federspiel
Journal:  J Infect Dis       Date:  2016-03-03       Impact factor: 5.226

6.  MicroRNAs and exosomes: key players in HIV pathogenesis.

Authors:  J Sadri Nahand; F Bokharaei-Salim; M Karimzadeh; M Moghoofei; S Karampoor; H R Mirzaei; A Tabibzadeh; A Jafari; A Ghaderi; Z Asemi; H Mirzaei; M R Hamblin
Journal:  HIV Med       Date:  2019-11-22       Impact factor: 3.180

Review 7.  Can early therapy reduce inflammation?

Authors:  Netanya G Sandler; Irini Sereti
Journal:  Curr Opin HIV AIDS       Date:  2014-01       Impact factor: 4.283

Review 8.  Initiation of antiretroviral therapy at high CD4 cell counts: does it reduce the risk of cardiovascular disease?

Authors:  Chris T Longenecker; Virginia A Triant
Journal:  Curr Opin HIV AIDS       Date:  2014-01       Impact factor: 4.283

9.  Current Treatment Options for HIV Elite Controllers: a Review.

Authors:  Katherine Promer; Maile Y Karris
Journal:  Curr Treat Options Infect Dis       Date:  2018-04-16

10.  Antiretroviral therapy for HIV controllers: Reasons for initiation and outcomes in the French ANRS-CO21 CODEX cohort.

Authors:  Léo Plaçais; Faroudy Boufassa; Camille Lécuroux; Elise Gardiennet; Véronique Avettand-Fenoel; Asier Saez-Cirion; Olivier Lambotte; Nicolas Noël
Journal:  EClinicalMedicine       Date:  2021-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.